4.4 Article

A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders

Journal

JAMA PSYCHIATRY
Volume 74, Issue 4, Pages 399-405

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/jamapsychiatry.2017.0080

Keywords

-

Categories

Funding

  1. Allergan
  2. Alkermes
  3. AstraZeneca
  4. BioHaven Pharmaceuticals
  5. Hoffman La-Roche
  6. Johnson & Johnson (Janssen)
  7. Merck
  8. Naurex
  9. Servier Pharmaceuticals
  10. Taisho Pharmaceuticals
  11. Teva
  12. Vistagen Therapeutics
  13. Sanofi
  14. AssureRx
  15. Janssen Research Development
  16. Mayo Foundation
  17. Myriad Genetics
  18. Pfizer
  19. Mayo
  20. Janssen Research & Development LLC
  21. Mitsubishi Tanabe Pharma Corporation
  22. Neuralstem Inc
  23. Sunovion
  24. Supernus Pharmaceuticals
  25. Teva Pharmaceuticals
  26. National Institute of Mental Health
  27. National Institute of Neurological Disease and Stroke
  28. Stanley Foundation
  29. Soterix
  30. Neuronetics
  31. Cervel Neurotherapeutics
  32. Department of Veterans Affairs
  33. Otsuka
  34. Acadia
  35. Cerecor
  36. Genentech
  37. Valeant
  38. Johnson Family Chair for Research in Psychiatry at Baylor College of Medicine
  39. Forum
  40. Gilead
  41. Takeda
  42. Xhale
  43. Clintara

Ask authors/readers for more resources

IMPORTANCE Several studies now provide evidence of ketamine hydrochloride's ability to produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment. Despite the relatively small sample sizes, lack of longer-term data on efficacy, and limited data on safety provided by these studies, they have led to increased use of ketamine as an off-label treatment for mood and other psychiatric disorders. OBSERVATIONS This review and consensus statement provides a general overview of the data on the use of ketamine for the treatment of mood disorders and highlights the limitations of the existing knowledge. While ketamine may be beneficial to some patients with mood disorders, it is important to consider the limitations of the available data and the potential risk associated with the drug when considering the treatment option. CONCLUSIONS AND RELEVANCE The suggestions provided are intended to facilitate clinical decision making and encourage an evidence-based approach to using ketamine in the treatment of psychiatric disorders considering the limited information that is currently available. This article provides information on potentially important issues related to the off-label treatment approach that should be considered to help ensure patient safety.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available